174 related articles for article (PubMed ID: 28958437)
1. A Thorough QT/QTc Study of Clobazam in Healthy Volunteers.
Tolbert D; Gordon J; Harris S; Walzer M; Bekersky I; Reid S
Clin Ther; 2017 Oct; 39(10):2073-2086. PubMed ID: 28958437
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
3. Vigabatrin Lacks Proarrhythmic Potential: Results from a Thorough QT/QTc Study in Healthy Volunteers.
Tolbert D; Reid S; Harris S; Bekersky I
Clin Ther; 2017 Aug; 39(8):1639-1648. PubMed ID: 28668627
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
5. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.
Saruwatari J; Ogusu N; Shimomasuda M; Nakashima H; Seo T; Tanikawa K; Tsuda Y; Nishimura M; Nagata R; Yasui-Furukori N; Kaneko S; Ishitsu T; Nakagawa K
Ther Drug Monit; 2014 Jun; 36(3):302-9. PubMed ID: 24345815
[TBL] [Abstract][Full Text] [Related]
6. Lacosamide cardiac safety: a thorough QT/QTc trial in healthy volunteers.
Kropeit D; Johnson M; Cawello W; Rudd GD; Horstmann R
Acta Neurol Scand; 2015 Nov; 132(5):346-54. PubMed ID: 25932544
[TBL] [Abstract][Full Text] [Related]
7. Drug-metabolism mechanism: Knowledge-based population pharmacokinetic approach for characterizing clobazam drug-drug interactions.
Tolbert D; Bekersky I; Chu HM; Ette EI
J Clin Pharmacol; 2016 Mar; 56(3):365-74. PubMed ID: 26224203
[TBL] [Abstract][Full Text] [Related]
8. Impact of Drug Interactions on Clobazam and N-Desmethylclobazam Concentrations in Pediatric Patients With Epilepsy.
Russell GR; Phelps SJ; Shelton CM; Wheless JW
Ther Drug Monit; 2018 Aug; 40(4):452-462. PubMed ID: 29746397
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2C19 polymorphisms on the clinical outcome of low-dose clobazam therapy in Japanese patients with epilepsy.
Hashi S; Yano I; Shibata M; Masuda S; Kinoshita M; Matsumoto R; Ikeda A; Takahashi R; Matsubara K
Eur J Clin Pharmacol; 2015 Jan; 71(1):51-8. PubMed ID: 25323806
[TBL] [Abstract][Full Text] [Related]
10. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics.
Tolbert D; Bekersky I; Chu HM; Ette EI
J Clin Pharmacol; 2016 Feb; 56(2):213-22. PubMed ID: 26139309
[TBL] [Abstract][Full Text] [Related]
11. Effect of Retosiban on Cardiac Repolarization in a Randomized, Placebo- and Positive-controlled, Crossover Thorough QT/QTc Study in Healthy Men and Women.
Stier B; Fossler M; Liu F; Caltabiano S
Clin Ther; 2015 Jul; 37(7):1541-54. PubMed ID: 26138866
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid.
Jullien V; Chhun S; Rey E; Dulac O; Tod M; Chiron C; Pons G
Clin Pharmacokinet; 2015 May; 54(5):527-36. PubMed ID: 25503589
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.
Giraud C; Treluyer JM; Rey E; Chiron C; Vincent J; Pons G; Tran A
Drug Metab Dispos; 2006 Apr; 34(4):608-11. PubMed ID: 16415114
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Overview of the Clinical Pharmacokinetics of Clobazam.
Tolbert D; Larsen F
J Clin Pharmacol; 2019 Jan; 59(1):7-19. PubMed ID: 30285275
[TBL] [Abstract][Full Text] [Related]
15. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.
Kosaki K; Tamura K; Sato R; Samejima H; Tanigawara Y; Takahashi T
Brain Dev; 2004 Dec; 26(8):530-4. PubMed ID: 15533655
[TBL] [Abstract][Full Text] [Related]
16. Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.
Yamamoto Y; Takahashi Y; Imai K; Mogami Y; Matsuda K; Nakai M; Kagawa Y; Inoue Y
Epilepsy Behav; 2014 May; 34():124-6. PubMed ID: 24742983
[TBL] [Abstract][Full Text] [Related]
17. Effects of Nemonoxacin on Thorough ECG QT/QTc Interval: A Randomized, Placebo- and Positive-controlled Crossover Study in Healthy Chinese Adults.
Zhao C; Lv Y; Li X; Hou F; Ma X; Wei M; Kang Z; Cui L; Xia Y; Liu Y; Tian J
Clin Ther; 2018 Jun; 40(6):983-992. PubMed ID: 29803534
[TBL] [Abstract][Full Text] [Related]
18. Effects of Celecoxib on the QTc Interval: A Thorough QT/QTc Study.
Kim S; Lee H; Ko JW; Kim JR
Clin Ther; 2019 Nov; 41(11):2204-2218. PubMed ID: 31564512
[TBL] [Abstract][Full Text] [Related]
19. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
